-
Shenzhen Kangtai Partners with AstraZeneca to Establish Vaccine JV in Beijing
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has formed a vaccine-focused partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN). The collaboration includes the establishment of a joint venture (JV) in Beijing aimed at developing and manufacturing novel vaccines for China and emerging markets. Joint Venture DetailsThe JV marks…
-
Shenzhen Kangtai Halts COVID-19 Vaccine Development Amid Market Shifts
•
Shenzhen based biopharmaceutical company Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the termination of its research and development efforts for the COVID – 19 inactivated vaccine (Vero cells). The decision was driven by the evolving nature of the novel coronavirus and the changing market environment for COVID…
-
Shenzhen Kangtai Begins Phase I Clinical Trial for 20-Valent Pneumococcal Vaccine
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the enrollment of the first patient in the Phase I study for its 20-valent pneumococcal polysaccharide conjugate vaccine. This vaccine is designed to prevent infectious diseases caused by 20 pneumococcal serotypes, targeting infants and children aged between 2 months…
-
Kangtai Biological Receives NMPA Approval for 20-Valent Pneumococcal Vaccine Clinical Trial
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading biopharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its 20-valent pneumococcal polysaccharide conjugate vaccine. The vaccine is designed to prevent infectious diseases caused by…
-
Kangtai Biological Partners with AstraZeneca and Beijing Daxing District to Boost Vaccine Market Presence
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a prominent biopharmaceutical company based in China, has entered into a strategic agreement with UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) and the Daxing district government of Beijing. The collaboration is focused on the vaccine sector, aiming to introduce new vaccines to the…
-
Kangtai Biological Products Co., Ltd. Expands Vaccine Access in South Asia with Bangladesh Deal
•
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a Chinese biopharmaceutical firm, has announced the signing of an authorized agency and technical transfer cooperation agreement with a company based in Bangladesh. The undisclosed Bangladeshi company will collaborate with Kangtai Bio on the 23-valent pneumococcal polysaccharide vaccine semi-finished stock solution. The…
-
Kangtai Biological Partners with Bahrain Pharma Firm on Strategic Vaccine Production Agreement
•
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601), a prominent player in China’s biotechnology sector, has entered into a supply and production licensing agreement with a leading pharmaceutical company based in Bahrain. This partnership focuses on a range of vaccines, including the 13-valent pneumococcal polysaccharide conjugate vaccine, the 23-valent pneumococcal…
-
Kangtai Biological Partners with Gennvax Egypt to Commercialize 13-Valent Pneumococcal Vaccine
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a Chinese biopharmaceutical company, has entered into an agency and technology transfer agreement with Egyptian firm Gennvax Egypt concerning Kangtai’s 13-valent pneumococcal polysaccharide conjugate vaccine. Under the terms of the agreement, the two companies will collaborate to advance the marketing approval of…
-
Kangtai Biological Expands Global Reach with Varicella Vaccine Licensing Deals
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a China-based biopharmaceutical company, has entered into licensing agreements with undisclosed pharmaceutical companies in Pakistan and India. These strategic partnerships aim to strengthen the regulatory filing, marketing, and distribution of Kangtai Bio’s varicella attenuated live vaccines in both countries. Vaccine Description and…
-
Kangtai Biological Partners with Indian Pharmaceutical Giant for 13-Valent Pneumonia Vaccine
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese biopharmaceutical company, has entered into a partnership with a top-tier Indian pharmaceutical company. The collaboration aims to facilitate the regulatory filing, marketing, and distribution of Kangtai Bio’s dual carrier 13-valent pneumonia vaccine in India. Indian Pharmaceutical Company’s Extensive ReachThe…
-
Shenzhen Kangtai Biological Partners with Saudi Importer for Pneumonia Vaccine Distribution
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with a drug importer in Saudi Arabia to promote the regulatory filing, marketing, and sales of its 13-valent and 23-valent pneumonia vaccines in the country. The local partner will handle the regulatory filing and approval process…
-
Shenzhen Kangtai Biological Partners with Biotis for 13-Valent Pneumococcal Vaccine in Indonesia
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has struck a partnership with Indonesian firm Biotis concerning a dual carrier 13-valent pneumococcal polysaccharide conjugate vaccine. This collaboration aims to enhance vaccine accessibility and public health initiatives in Indonesia. Agreement Details and Technical CollaborationAs per the agreement, Kangtai Bio will…
-
Kangtai Bio Partners with AstraZeneca and Combiphar to Expand Vaccine Collaboration
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese vaccine manufacturer, has entered into a strategic partnership with UK-based AstraZeneca (AZ, NASDAQ: AZN) and Indonesian pharmaceutical company Combiphar. The collaboration aims to strengthen the cooperation between China and Indonesia in the vaccine sector. Under the terms of the…
-
Kangtai Biological Partners with Pakistani Firm for Pneumonia Vaccine Expansion
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with a local company in Pakistan. The collaboration aims to work together on the regulatory filing, distribution, and licensing of Kangtai’s 13-valent and 23-valent pneumonia vaccines in the Pakistani market. Pakistan’s Vaccination Plan and Market OpportunityPakistan,…
-
Kangtai Biological Begins Phase I Trial for Tetravalent Influenza Vaccine
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment in a Phase I clinical study for its tetravalent influenza virus split vaccine. This marks a significant step in the development of a vaccine designed to provide broader protection against influenza, particularly for individuals aged…
-
Kangtai Biological Completes Phase III Clinical Data Analysis for COVID-19 Vaccine
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the completion of the analysis of key Phase III clinical data for its in-house developed COVID-19 inactivated vaccine (Vero cells). The study assessed the vaccine’s efficacy and safety in a global, multi-center, randomized, double-blind, placebo-controlled trial. Study DetailsThe Phase…
-
Kangtai Bio Partners with Philippine Firm on Pneumonia Vaccines
•
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has partnered with an unnamed Philippine enterprise to promote its 13-valent and 23-valent pneumonia vaccines in the Philippines. The collaboration aims to enhance regulatory filing, promotion, distribution, marketing, and sales, increasing accessibility and affordability in the Philippines and other emerging markets. Vaccine…
